About Rochelle Walensky, MD, MPH

Dr. Rochelle Walensky, MD, MPH, is Professor of Medicine at Harvard Medical School and a practicing Infectious Disease physician at Massachusetts General Hospital and Brigham and Women's Hospital.

Dr. Walensky's research interests focus on model-based analyses of the cost-effectiveness of HIV testing, care, and prevention strategies to inform HIV/AIDS policy internationally and domestically.

Using both traditional novel methods of microsimulation modeling and decision analysis, Dr. Walensky has been active in and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.

In addition, Dr. Walensky has been influential in advancing international health policy towards the promotion of HIV treatment as prevention (TasP) and the adoption of other effective and efficient strategies of HIV care.

Dr. Walensky serves as Chair of the Office of AIDS Research Advisory Council (NIH) and as a member of the US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. 

Departments, Centers, & Programs:

Clinical Interests:



Infectious Disease Associates
55 Fruit Street
Boston, MA 02114-2696

Medical Education

  • Harvard T. H. Chan School of Public Health
  • MD, Johns Hopkins University School of Medicine
  • Residency, The Johns Hopkins Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Infectious Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Rochelle Walensky is Co-Director of the Medical Practice Evaluation Center and, within that Center, is the Director of the Program in Epidemiology and Outcomes Research in Infectious Diseases.

Dr. Walensky's HIV-related research interests include the promotion of routine HIV counseling, testing and referral and the economic evaluation of alternative HIV testing and treatment policies.  Dr. Walensky has published work on the impact of routine HIV screening, on the clinical and cost-effectiveness of HIV vaccines of varying efficacies, on the impact of generic antiretroviral, and on the preventive impact of early antiretroviral therapy.  Her research is conducted both in the US and abroad.

Current projects include: 1) An analysis of the economic impact of economic incentives to promote ART retention; 2) the years of life saved associated with ART in South Africa; and 3) the development of and HIV testing program in KwaZulu-Natal, South Africa and in a refugee setting in Uganda.

Within the Program in Epidemiology and Outcomes Research in Infectious Diseases, Dr. Walensky has expanded her research portfolio to include a clinical trial of documenting MRSA clearance; the cost-effectiveness of diagnostic strategies to remove of MRSA/VRE-related contact precautions; and resource utilization associated with antibiotic allergies. She welcomes the opportunity to expand clinical research within general infectious diseases.


  • View my most recent publications at PubMed

    Selected References:

    1. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR.  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.  Ann Intern Med. 2013 Jan 15; 158(2):84-92.
    2. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Want L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. The cost-effectiveness of HIV treatment as prevention: analysis of HPTN 052. N Eng J Med. 2013; 369(18):1715?1725.